Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

NCT07628127 is registered in ClinicalTrials.gov with Verdiva Bio Dev Limited as lead sponsor.

NCT NCT07628127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07628127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
Lead sponsor
Verdiva Bio Dev Limited
Phase
Phase 1
Overall status
Recruiting
Start date
July 6, 2026
Completion date
March 31, 2028
Enrollment
332 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight